Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively
assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET
scanning of patients with suspected cardiac amyloidosis.